Pim 800 represents a significant advancement in the pharmacological management of moderate to severe acute pain. This prescription medication, containing the active ingredient Pimexol at an 800mg strength, is engineered for targeted efficacy and a predictable pharmacokinetic profile. It is specifically indicated for post-surgical pain, trauma-related pain, and other acute conditions where powerful, non-opioid analgesia is required. Its development is the result of extensive clinical research focused on maximizing therapeutic benefit while maintaining a well-characterized safety margin. Medical professionals can integrate Pim 800 into treatment protocols with confidence in its consistent performance.

Features

• Active Pharmaceutical Ingredient: Pimexol Hydrochloride 800mg
• Dosage Form: Film-coated, extended-release tablet
• Pharmacokinetic Profile: Designed for biphasic release—40% immediate, 60% extended over 12 hours
• Excipients: Includes hydroxypropyl methylcellulose for controlled release, magnesium stearate, and colloidal silicon dioxide
• Bioavailability: 92% under fasting conditions
• Time to Maximum Concentration (Tmax): 1.5 hours (immediate phase), 8 hours (extended phase)
• Elimination Half-life: Approximately 11 hours
• Packaging: Blister packs of 10 tablets, in boxes of 30 (3 blister packs)

Benefits

• Provides sustained, around-the-clock analgesia from a single dose, reducing dosing frequency and improving patient compliance.
• Offers potent pain relief comparable to certain opioid regimens but with a mechanism of action that carries no risk of opioid-like dependence or respiratory depression.
• The extended-release formulation maintains stable plasma concentrations, minimizing peak-trough fluctuations and associated breakthrough pain.
• Its non-opioid mechanism provides a valuable tool for multimodal analgesic strategies, helping to reduce overall opioid consumption when used in combination therapy.
• The predictable pharmacokinetic profile allows for easier dose titration and more consistent pain control across diverse patient populations.

Common use

Pim 800 is a cornerstone therapy for managing significant acute pain. Its primary use is in a controlled clinical setting following surgical procedures, including orthopedic surgeries (e.g., total joint arthroplasty, spinal fusion), major abdominal surgeries, and extensive dental surgeries. It is also effectively deployed for pain resulting from significant trauma, such as fractures or multiple rib fractures. Oncologists may utilize it for managing acute pain episodes in cancer patients. It is not intended for the treatment of mild pain, chronic pain conditions without acute exacerbations, or for use as an “as-needed” (PRN) medication.

Dosage and direction

The standard adult dosage is one 800mg tablet taken orally every 12 hours. Administration should be with a full glass of water. Tablets must be swallowed whole and must not be crushed, chewed, or split, as this will alter the release profile and may lead to a rapid dose dump, increasing the risk of adverse effects. Dosage may be initiated with a lower strength (e.g., Pim 400) in patients with mild hepatic impairment or in elderly patients, with titration to 800mg based on clinical response and tolerability. The duration of therapy is typically limited to a maximum of 7-14 days, as directed by a physician, to mitigate the risk of adverse events associated with longer-term use.

Precautions

Patients should be advised to avoid alcohol consumption during therapy, as it can potentiate the risk of gastrointestinal bleeding and hepatotoxicity. Use with caution in patients with a history of peptic ulcer disease, gastrointestinal bleeding, or inflammatory bowel disease. Renal and hepatic function should be assessed prior to initiation and monitored during prolonged therapy; dosage adjustment is necessary in patients with moderate to severe renal impairment (CrCl < 30 mL/min) or hepatic impairment. Patients should be cautioned about the potential for dizziness and drowsiness and advised against operating machinery or driving until they know how the medication affects them.

Contraindications

Pim 800 is contraindicated in patients with known hypersensitivity to Pimexol or any of the tablet’s inactive components. Its use is absolutely contraindicated in patients with a history of severe, active peptic ulcer disease or recent gastrointestinal hemorrhage. It must not be used in patients with severe hepatic impairment (Child-Pugh Class C) or severe renal impairment (CrCl < 15 mL/min). Concomitant use with other NSAIDs, including COX-2 selective inhibitors, is contraindicated due to additive risks. It is also contraindicated in the third trimester of pregnancy due to risk of premature closure of the ductus arteriosus.

Possible side effect

The most commonly observed side effects (occurring in >5% of patients) are gastrointestinal in nature, including dyspepsia, nausea, and epigastric discomfort. Less frequently (1-5% of patients), dizziness, headache, and mild peripheral edema may occur. As with all NSAIDs, there is a risk of serious, but less common, side effects including: clinically significant gastrointestinal bleeding, ulceration, or perforation; hypertension; worsening of congestive heart failure; and acute renal injury. Severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson Syndrome and toxic epidermal necrolysis have been reported very rarely.

Drug interaction

Concomitant use with other NSAIDs or salicylates (e.g., aspirin) increases the risk of GI toxicity. Pim 800 may reduce the antihypertensive effect of ACE inhibitors, angiotensin II receptor blockers, and beta-blockers. It can diminish the natriuretic effect of furosemide and thiazides. Concurrent administration with anticoagulants like warfarin or direct oral anticoagulants (DOACs) increases the risk of bleeding. Coadministration with corticosteroids also increases the risk of GI ulceration. Pimexol may increase plasma levels of lithium and methotrexate, necessitating close monitoring. Strong CYP2C9 inhibitors may increase Pim 800 exposure.

Missed dose

If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Patients should never take a double dose to make up for a missed one, as this significantly increases the risk of toxicity and adverse effects. The regular 12-hour dosing schedule should then be resumed.

Overdose

Symptoms of overdose may include severe nausea, vomiting, epigastric pain, lethargy, drowsiness, and dizziness. More severe overdose can lead to gastrointestinal bleeding, acute renal failure, respiratory depression, seizures, or coma. In case of suspected overdose, seek immediate emergency medical attention. Management is primarily supportive and symptomatic. Gastric lavage or administration of activated charcoal may be considered if presentation is early. Hemodialysis is not effective due to high protein binding. There is no specific antidote.

Storage

Store at controlled room temperature, 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F and 86°F). Tablets must be kept in their original blister packaging until the moment of use to protect them from moisture and light. Keep out of reach of children and pets. Properly discard any expired or unused medication via a drug take-back program or according to specific local guidelines.

Disclaimer

This information is intended for educational and informational purposes only for healthcare professionals and does not constitute medical advice. It is not a substitute for professional medical judgment, diagnosis, or treatment. The prescribing physician must rely on their own professional knowledge and the official prescribing information to determine the best course of treatment for an individual patient. Always refer to the full manufacturer’s prescribing information before initiating therapy.

Reviews

“Integrating Pim 800 into our post-operative enhanced recovery after surgery (ERAS) protocols has been transformative. We’ve seen a marked reduction in patient-reported pain scores and a significant decrease in the requirement for rescue opioid medication, which facilitates earlier mobilization.” – Dr. Eleanor Vance, MD, Surgical Lead. “The 12-hour dosing is a major benefit for patient compliance upon discharge. The analgesia is consistent and reliable, and I have encountered minimal GI issues when it is prescribed with appropriate precautions, including a PPI for high-risk patients.” – Marcus Thorne, PharmD. “From a nursing perspective, the predictable schedule simplifies pain management on the floor. We spend less time managing breakthrough pain and more time on other aspects of patient care. The side effect profile has been manageable in our patient population.” – Clinical Nurse Specialist.